| 查看: 167 | 回复: 0 | |||
| 当前主题已经存档。 | |||
abcd888898银虫 (正式写手)
|
[交流]
【转帖】Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue
|
||
|
Emisphere earns 2 million US dollar milestone payment(13 Jan 2010) Novo Nordisk today announced that it has initiated its first phase 1 clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a 2 million dollar payment to Emisphere Technologies, Inc., whose proprietary Eligen® Technology is used in the formulation of NN9924. GLP-1 (Glucagon-Like Peptide-1) is a natural hormone involved in controlling blood sugar levels. It stimulates the release of insulin only when blood sugar levels become too high. In people with type 2 diabetes, GLP-1 secretion is often impaired. The aim of the trial, which is conducted in the UK, is to investigate the safety, tolerability and bioavailability of NN9924 in healthy volunteers. Results from the trial, which is planned to enrol about 155 people, are expected to be reported in 2011. There are many challenges in developing a formulation of GLP-1 for oral use, in particular obtaining adequate bioavailability (absorption of the drug in the body). NN9924 addresses some of the key challenges, and utilises the Eligen® formulation technology from Emisphere to facilitate GLP-1 absorption from the gut. |
回复此楼» 猜你喜欢
2026申博
已经有0人回复
-
合成
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有127人回复
-
氨基酸的酰化反应，求大佬解答
已经有0人回复
-
26年申博——已发SCI6篇
已经有13人回复
-
碱缸的配制
已经有5人回复
-
新！澳门科技大学诚招2026年秋季药剂学/生物材料方向博士研究生（申请-考核制）
已经有18人回复
-
澳科大药学院诚招2026年秋季纳米医学/生物材料博士研究生
已经有16人回复
-
医药口服制剂辅料应用
已经有0人回复
-
全新推出Tguide®靶向递送方案，突破99% T细胞转染效率
已经有1人回复